Corcept Therapeutics

CORT · Nasdaq · United States

Share price · CORT

$67.79-50.31 (-42.60%) 3M

close as of 2026-11-18 · 24h delayed · vol 745K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CORT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 23 Oct 2026-20.1%
  2. 30 Jul 2026+27.3%
  3. 27 May 2026+10.4%
  4. 13 May 2026+11.6%
  5. 1 May 2026+10.5%
  6. 25 Mar 2026+19.7%
  7. 31 Dec 2025-50.4%
  8. 30 Dec 2025-12.1%

    Nothing announced by CORT that day or the session before.

  9. 16 Dec 2025-7.1%

    Nothing announced by CORT that day or the session before.

Share of unusual movement by asset

For each asset, the share of CORT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Relacorilant (Lifyorli) (Lifyorli)
events and moves
1676%
mifepristone (Korlym)
events and moves
1shown from 8 days
Dazucorilant
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—6%
Sessions with no dated event—18%

Assets

(4 total)
4Total Assets
2Approved
0Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
mifepristone(Korlym)
Approved
Progesterone receptor; Glucocorticoid receptorSmall molecule
Cushing's Syndrome
Approved
Glucocorticoid receptorSmall molecule
Cushing's SyndromeOvarian Cancer
Phase 2
Glucocorticoid receptorSmall molecule
Amyotrophic Lateral Sclerosis
Phase 2
Glucocorticoid receptorSmall molecule
MASH / NASH

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Relacorilant (Lifyorli)Phase 2Cushing Syndrome
Est. primary completion 2026-12 · NCT03604198 · CT.gov ↗
What to watch
2027 (2)
September 2027 (1)
Relacorilant (Lifyorli)Phase 2Adenocarcinoma, Carcinoma, Pancreatic Ductal
Est. primary completion 2027-09 · NCT07259317 · CT.gov ↗
What to watch
December 2027 (1)
Relacorilant (Lifyorli)Phase 2Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
Est. primary completion 2027-12 · NCT06906341 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

17 December 2026FDA action dateRelacorilant (Lifyorli)PDUFA date for the relacorilant NDA resubmission in Cushing's syndrome
US, FDA · Corcept Therapeutics Incorporated · Source ↗

Recent

17 June 2026Filing submittedRelacorilant (Lifyorli)Corcept resubmits the relacorilant NDA in Cushing's syndrome to the FDA
US, FDA · Corcept Therapeutics Incorporated · Source ↗
27 May 2026Complete response letterRelacorilant (Lifyorli)FDA issued a complete response letter
US, FDA · Source ↗
March 2026ApprovalRelacorilant (Lifyorli)FDA approves Lifyorli for platinum-resistant ovarian cancer
US, FDA · Source ↗
22 January 2026Topline resultRelacorilant (Lifyorli)Phase 3 ROSELLA of relacorilant met its overall survival primary endpoint
Corcept Therapeutics · Source ↗
31 December 2025Complete response letterRelacorilantFDA issues complete response letter for relacorilant in hypercortisolism
US, FDA · Corcept Therapeutics · Source ↗
December 2024Topline resultDazucorilantPhase 2 DAZALS (NCT05407324) of dazucorilant in ALS did not meet its primary endpoint (change in ALSFRS-R)
Corcept Therapeutics · Source ↗
December 2024Filing submittedRelacorilant (Lifyorli)Corcept submits the relacorilant NDA in endogenous hypercortisolism
US, FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$340M$57M$99M+ $272M short-term inv.—$143M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$256M$54M$112M+ $197M short-term inv.—$34M operating cash flowreport ↗
2026-Q1$165M$66M$110M+ $229M short-term inv.$32M-$17M operating cash flowreport ↗
2025-Q3$208M$69M$125M+ $297M short-term inv.—$54M operating cash flowreport ↗
2025-Q2$194M$60M$103M+ $239M short-term inv.—$44M operating cash flowreport ↗
2025-Q1$157M$61M$90M+ $233M short-term inv.—$5.1M operating cash flowreport ↗
2024-Q3$183M$59M$137M+ $243M short-term inv.—$74M operating cash flowreport ↗
2024-Q2$164M$59M$129M+ $345M short-term inv.—$41M operating cash flowreport ↗
2024-Q1$147M$59M$150M+ $261M short-term inv.—$24M operating cash flowreport ↗
2023-Q3$124M$46M$112M+ $243M short-term inv.—$53M operating cash flowreport ↗
2023-Q2$118M$43M$172M+ $191M short-term inv.—$42M operating cash flowreport ↗
2023-Q1$106M$41M$300M+ $165M short-term inv.—$26M operating cash flowreport ↗
2022-Q3$102M$33M$50M+ $346M short-term inv.—$34M operating cash flowreport ↗
2022-Q2$103M$33M$35M+ $335M short-term inv.—$18M operating cash flowreport ↗
2022-Q1$94M$28M$62M+ $284M short-term inv.—$35M operating cash flowreport ↗
2021-Q3$96M$28M$95M+ $267M short-term inv.—$49M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$761M$255M$121M+ $252M short-term inv.—$142M operating cash flowreport ↗

Corcept reported full-year 2025 revenue of $761.4M, up 12.8% YoY, and R&D spend of $254.9M, up 3.2% YoY. Cash and investments were $532.4M at December 31, 2025, and net income was $99.7M, or $0.82 diluted EPS. The company guided full-year 2026 revenue to $900 million to $1,000 million. It is engaged with the FDA on relacorilant in Cushing’s syndrome after a Complete Response Letter, while its NDA for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer has a July 11, 2026 PDUFA date and the related MAA is under EMA review. ROSELLA met both dual primary endpoints with a 35% reduction in risk of death, MOMENTUM results are scheduled for an ACC presentation in March, BELLA and MONARCH results are expected by the end of 2026, and a Phase 3 dazucorilant trial in ALS is planned to begin mid-2026. Corcept also paid $245.9M for common stock purchases, net option exercises and restricted stock vesting, and completed its specialty pharmacy transition.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$675M$247M$128M+ $256M short-term inv.—$198M operating cash flowreport ↗
2023-FY$482M$184M$136M+ $233M short-term inv.—$127M operating cash flowreport ↗
2022-FY$402M$131M$66M+ $365M short-term inv.—$120M operating cash flowreport ↗
2021-FY$366M$114M$78M+ $146M short-term inv.—$168M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($3.3M), 112 sales ($98.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13WILSON JAMES N · directorOpen-market sale2,191$71.80$157KForm 4
2026-11-13WILSON JAMES N · directorOpen-market sale7,221$72.87$526KForm 4
2026-11-13WILSON JAMES N · directorOpen-market sale563$73.42$41KForm 4
2026-11-13WILSON JAMES N · directorOpen-market sale25$74.28$2KForm 4
2026-11-10Swisher Daniel N JR · directorOption exercise1,100$14.08$15KForm 4
2026-11-10Swisher Daniel N JR · directorOption exercise400$10.50$4KForm 4
2026-11-10Swisher Daniel N JR · directorOpen-market sale1,500$74.07$111KForm 4
2026-11-10Swisher Daniel N JR · directorOption exercise (derivative)1,100——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 348 reporting institutions held 79.2M shares ($2.8B, 72.4% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.12,151,276$489.8M
2RENAISSANCE TECHNOLOGIES LLC5,682,783$229.1M
3VANGUARD PORTFOLIO MANAGEMENT LLC4,820,568$194.3M
4VANGUARD CAPITAL MANAGEMENT LLC4,077,196$164.4M
5Parallel Advisors, LLC3,977,404$160.3M
6STATE STREET CORP3,200,946$129.0M
7FMR LLC3,190,192$128.6M
8GEODE CAPITAL MANAGEMENT, LLC2,713,519$109.4M
9FIRST TRUST ADVISORS LP2,173,376$87.6M
10DIMENSIONAL FUND ADVISORS LP1,553,135$62.6M
11TANG CAPITAL MANAGEMENT LLC1,500,000$60.5M
12UBS Group AG1,363,668$55.0M
13D. E. Shaw & Co., Inc.1,181,348$47.6M
14CHARLES SCHWAB INVESTMENT MANAGEMENT INC1,119,959$45.1M
15MORGAN STANLEY1,018,845$41.1M